Drug-induced liver disease

Current Opinion in Gastroenterology

Volumn 17, Issue 3, 2001, Pages 232-241

  Marino, Gustavo ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; AMFEBUTAMONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; CELECOXIB; CERIVASTATIN; CLAVULANIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DIDANOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPECAC; LAMOTRIGINE; MEVINOLIN; NEFAZODONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRAVASTATIN; PSYCHOTROPIC AGENT; SIMVASTATIN; STAVUDINE; TRAZODONE; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; VENLAFAXINE; ZAFIRLUKAST;

ALCOHOL CONSUMPTION; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; LIVER DISEASE; LIVER TOXICITY; REVIEW;

EID: 0035052030     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200105000-00006     Document Type: Review

References (106)

1. Drug induced liver disease
2. Clinical assessment of drug-induced disease
3. Mechanisms of adverse drug reactions
4. Drug-induced liver disease
5. Evaluation of abnormal liver-enzyme results in asymptomatic patients
6. Nimesulide-induced acute hepatitis: Evidence from six cases
7. COX 2 inhibitor and fulminant hepatic failure
8. Nimesulide-induced hepatitis and acute liver failure
9. Fatal hepatitis associated with nimesulide
10. Celecoxib-induced acute pancreatitis and hepatitis: A case report
11. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
12. Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction
13. Severe liver injury after treatment with leukotriene receptor antagonist zafirlukast
14. Acute hepatitis induced by bupropion
15. The rise of serum aminotransferases in a patient treated with bupropion
16. Ischemic hepatitis: Clinical presentation and pathogenesis
17. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series
18. Fulminant hepatitis failure induced by lamotrigine
19. Potential hepatotoxicity of lamotrigine
20. Acute hepatitis after lamotrigine administration
21. Reversible nefazodone-induced liver failure
22. Nefazodone-induced acute liver failure
23. Trazodone-induced hepatotoxicity: A case report with comments on drug-induced hepatotoxicity
24. Venlafaxine-associated hepatitis
25. A distinctive histologic pattern of liver injury in HIV positive patients on HAART: A possible hepatotoxic effect of protease inhibitors
26. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
27. Mitochondrial toxicity of antiviral drugs
28. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
29. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV) infection
30. Didanosine-induced hepatitis
31. Hepatic toxicity associated with 2′-3′ dideoxynosine in children with AIDS
32. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
33. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association
34. HLA association of amoxicillin-clavulanate-induced hepatitis
35. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid
36. Intrahepatic cholestasis due to ticarcillin-clavulanate
37. Acute eosinophilic hepatitis from trovafloxacin
38. Trovafloxacin-induced acute hepatitis
39. Trevafloxacin: An overview
40. Temafloxacin syndrome: Review of 95 cases
41. Comparative tolerability of the newer fluoroquinolone antibacterials
42. Fatal subfulminant hepatic failure with ofloxacin
43. Long-term safety of hepatic hydroxymethyl glutaryl Coenzyme A reductase inhibitors
44. Defining patient risks from expanded preventive therapies
45. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits
46. Troglitazene-associated hepatic failure
47. Severe but reversible hepatitis induced by troglitazone
48. Troglitazone-associated hepatotoxicity treated successfully with steroids
49. Rapid-onset subfulminant liver failure associated with troglitazone
50. Hepatic injury due to troglitazone
51. Treglitazone-induced fulminant hepatitis: Report of a case with autopsy findings
52. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
53. Troglitazone-induced fulminant hepatic failure
54. The role of conjugation in hepatotoxicity of trogtitazone in human and porcine hepatocyte cultures
55. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
56. Hepatic failure in a patient taking rosiglitazene
57. Hepatocellular injury in a patient receiving rosiglitazone: A case report
58. Rosiglitazone and hepatic failure
59. Editor's Note: Correction: Liver injury and rosiglitazone
60. Rosiglitazone and liver failure
61. Rosiglitazone toxicity
62. Isolated elevation of alkaline phosphatase level associated with rosiglitazone
63. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans
64. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac induced hepatitis
65. Transaminase elevations in patients receiving bovine or porcine heparin
66. Cholestatic liver reaction and heparin therapy
67. Cholestatic liver reaction during heparin therapy
68. Hepatotoxicity of botanicals
69. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes
70. Minocycline-induced hepatitis
71. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis
72. Calcium channel blockers and hepatotoxicity
73. Fatal hepatitis associated with ranitidine
74. Hydrazine, cancer, the internet, isoniazid, and the liver
75. Fatal hepatorenal failure associated with hydrazine sulfate
76. Tolcapone in stable Parkinson's disease: Efficacy and safety of long term treatment
77. Tolcapone-related fulminant hepatitis
78. Effects of long-term administration of the antiepileptic drug sodium valproate upon the ultrastructure of hepatocytes in rats
79. Change in occurrence of paracetamol overdose in UK after introduction of blister packs
80. Reduction in incidence of severe paracetamol poisoning
81. Prevention of paracetamol poisoning
82. Use of liver transplantation in patients with acute liver failure
83. Accidental paracetamol overdosing and fulminant hepatic failure in children
84. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity
85. Acetaminophen intoxication during treatment: What you don't know can hurt you
86. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of a therapeutic misadventure
87. Acetaminophen toxicity in an urban county hospital
88. Paracetamol, alcohol and the liver
89. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults
90. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose
91. Endotoxin pretreatment protects against the hepatotoxicity of acetaminophen and carbon tetrachloride: Role of cytochrome P450 suppression
92. Protective effect of leaf extract of Ficus hispida Linn. against paracetamol-induced hepatotoxicity in rats
93. Nicotinamide and methionine reduce the liver toxic effect of methotrexate
94. Inducers of cytochrome p450 2E1 enhance methotrexate-induced hepatotoxicity
95. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial
96. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis
97. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
98. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: Report of two cases
99. Oral contraceptive use and focal nodular hyperplasia of the liver
100. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
101. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
102. Hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus and the effect of hepatitis B or C virus infection
103. Safety of disease modifying antirheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis